Following Hurricane Milton’s catastrophic landfall, Governor Ron DeSantis has requested an Expedited Major Disaster Declaration to support Florida's response and recovery efforts. U.S. Senator Marco Rubio (R-FL), U.S. Representative Vern Buchanan (R-FL), and members...
News
Latest News
Photos: Rubio Joins U.S. Coast Guard Post-Hurricane Milton
Following Hurricane Milton’s catastrophic landfall in Florida, U.S. Senator Marco Rubio (R-FL) joined the U.S. Coast Guard to survey impacted areas across the State. Photos are courtesy of Senator Rubio’s office. Senator Rubio joins the U.S. Coast Guard for a flyover...
Next Week: Rubio Staff Hosts Mobile Office Hours
U.S. Senator Marco Rubio’s (R-FL) office will host in-person Mobile Office Hours next week to assist constituents with federal casework issues in their respective local communities. These office hours offer constituents who do not live close to one of Senator Rubio’s...
Rubio, Scott Support Seminole Tribe’s Request for Pre-landfall Emergency Declaration for Milton
Major Hurricane Milton is expected to make landfall in Florida, bringing with it devastating storm surge, winds, and inland flooding. The Seminole Tribe of Florida should have access to the federal resources required for emergency response and recovery preparations on...
Rubio, Scott to POTUS: Prepare for Hurricane Impacts to Port of Tampa Bay
Major Hurricane Milton is forecasted to potentially hinder or obstruct the Port of Tampa Bay, which receives more than 40 percent of Florida’s petroleum products. It’s crucial for the federal government to expedite all requested measures to protect Florida’s economy...
Rubio, Scott Support Florida’s Request for Pre-landfall Emergency Declaration Ahead of Hurricane Milton
Major Hurricane Milton is forecasted to impact Florida with devastating storm surge, winds, and inland flooding. After just being hit by Hurricane Helene, it’s crucial for the State of Florida to have the support of the federal government. U.S. Senators Marco Rubio...
Rubio Seeks Answers on Pharmacy Distribution of Abortion Drug
On January 3, 2023, the U.S. Food and Drug Administration (FDA) posted a new policy that allows pharmacies to distribute the chemical abortion pill mifepristone and remove the in-person distribution requirement. Data shows mifepristone is dangerous, which is why women using the drug to induce a chemical abortion were previously required to have medical supervision.
U.S. Senator Marco Rubio (R-FL) and Representative Andrew Clyde (R-GA) sent a letter to Government Accountability Office (GAO) Comptroller General Gene Dodaro urging the GAO to evaluate if the FDA’s change in guidance is considered a “rule” and subject to Congressional review under the Congressional Review Act.
- “We write to seek your review of whether the January 2023 REMS Modification for mifepristone, issued by the FDA, constitutes a ‘rule’ for purposes of the Congressional Review Act (CRA).”
- “The FDA’s update appears to prescribe detailed policy. For these reasons, we respectfully request a determination as to whether or not this ‘rule’ is applicable under the CRA. Please respond with your determination by February 14, 2023.”
Senators Cindy Hyde-Smith (R-MS), Mike Lee (R-UT), Thom Tillis (R-NC), Roger Marshall (R-KS), Mike Braun (R-IN), Rick Scott (R-FL), Roger Wicker (R-MS) and 27 members of the House also signed the letter.
Want more? The full text of the letter is below.
Dear Comptroller General Dodaro:
On January 3, 2023, the U.S. Food & Drug Administration (FDA) posted a new policy that increases access and consumption of mifepristone. We write to seek your review of whether the January 2023 REMS Modification for mifepristone, issued by the FDA, constitutes a “rule” for purposes of the Congressional Review Act (CRA).
With limited exceptions, the CRA defines a “rule” as follows:
‘[R]ule’ means the whole or part of an agency statement of general or particular applicability and future effect designed to implement, interpret, or prescribe law or policy or describing the organization, procedure, or practice requirements of an agency and includes the approval or prescription for the future of rates, wages, corporate or financial structures or reorganizations thereof, prices, facilities, appliances, services or allowances therefor or of valuations, costs, or accounting, or practices bearing on any of the foregoing.”
Based upon this broad definition, the Government Accountability Office has rightly pointed out that “agency pronouncements may be rules within the definition of 5 U.S.C. § 551 and the CRA, even if they are not subject to notice and comment rulemaking requirements under section 553.”
The FDA’s update appears to prescribe detailed policy. For these reasons, we respectfully request a determination as to whether or not this “rule” is applicable under the CRA. Please respond with your determination by February 14, 2023.
Sincerely,